Features of Central Hemodynamics in Patients with Diffuse Toxic Goiter

Авторы

  • Yu.M. Urmanova Alfraganus University, Department of Internal Medicine Автор
  • A.V. Alimov Republican Specialized Scientific and Practical Medical Center of Endocrinology Автор
  • H.J. Khasanova Alfraganus University, Department of Internal Medicine Автор
  • Yu.S. Khamroeva Alfraganus University, Department of Internal Medicine Автор
  • D.U. Yusufkhonova Alfraganus University, Department of Internal Medicine Автор

Ключевые слова:

Graves' disease, hemodynamics, degree

Аннотация

The aim of the study isto study the features of central hemodynamics in patients with diffuse toxic goiter. Material and methods of research. 32 people were examined, including 22 women, 10 men, average age49.2±1.62years (for women -47±1.76years, for men -42±2.6years) Research methods – general clinical, biochemical (bilirubin, direct, indirect, ALT, AST, PTI, coagulogram, CRP), hormonal (TSH, free thyroxine, antibodies to thyroid peroxidase, to thyroglobulin and thyrocyte receptors, prolactin in the blood),anthropometric calculations (height (cm), weight (kg), BMI (kg/m2), waist circumference, waist circumference) and instrumental: ECG, echo-ECG, ultrasound of the thyroid gland, internal organs, chest X-ray Research results. When analyzing echocardiography data in patients with thyrotoxicosis syndromevisiblethat in the general group of patients, a reliable decrease in the indicators of end-diastolic volume and end-diastolic volume and a reliable decrease in the ratio of peaks E and A in relation to the control were observed. An analysis of echocardiography parameters in patients with thyrotoxicosis depending on the clinical form showed that in the overt form, the EDV and ESV values, peak E, and the E/A ratio are significantly reduced. In the subclinical form, the IVS and peak A values ​​are significantly increased, and a significant decrease in ESV is observed. Conclusions.Echocardiographic signs of hemodynamic disturbances in thyrotoxicosis can be detected even before the manifestation of clinical symptoms of thyrotoxic heart disease.

Tibbiyot muqovasi

Загрузки

Indeks havolalari

Google Scholar Zenodo OpenAIRE BASE OpenAlex Semantic Scholar DataCite

Опубликован

2026-11-11

Выпуск

№ 11 (2026): Ноябрь 2026

Раздел

Articles

Как цитировать

Features of Central Hemodynamics in Patients with Diffuse Toxic Goiter. (2026). Tibbiyot, 11, 71-78. https://reandpub.uz/tibbiyot/article/view/1528

Библиографические ссылки

1.Sviridenko N.Yu., Tugeeva E.F., Aripov M.A., Buziashvili Yu.I. Functional reserve of the heart in patients with diffuse toxic goiter after drug restoration with euthyroidism-thiamazole // Problems of Endocrinology, 2009. - No. 3. - P. 21-24.

Troshina E.A., Sviridenko N.Yu. Federal clinical guidelines // Problems of endocrinology, 6, 2014, P-67.77.

Tadeev V.V. Based on the clinical guidelines of the European Thyroid Association for the diagnosis and treatment of subclinical thyrotoxicosis // Clinical and experimental thyroidology. Moscow 2016. P.11-15.

Khokhlov A.L., Leinova E.V. Cardiovascular pathology in thyrotoxicosis: dependence on the age of patients and duration of the disease // Clinical Gerontology, 2018. - V. 14. - No. 3. - P. 22-24.

Shulgina V.Yu., Melnichenko G.A., Syrkin A.L., Shornikov S.B. Prognostic factors of unfavorable outcome of thyrotoxic cardiomyopathy // Cardiology, 2007. - V. 47. - No. 11. - P. 26-29.

Naser JA, Pislaru S, Stan MN, et alIncidence, risk factors, natural history and outcomes of heart failure in patients with Graves' disease//Heart 2022;108:868-874.

GRISWOLD D, KEATING JH Jr. Cardiac dysfunction in hyperthyroidism; a study of 810 cases. //Am Heart J. 1949 Dec;38(6):813-22. doi: 10.1016/0002-8703(49)90883-2

Vargas-Uricoechea H, Bonelo-Perdomo A, Sierra-Torres CH. Effects of thyroid hormones on the heart. // Clin Investig Arterioscler 2014;26:296–309.doi:10.1016/j.arteri.2014.07.003

Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the heart. Methodist Debakey Cardiovasc J 2017;13:60–3.doi:10.14797/mdcj-13-2-60

Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction //European journal of endocrinology. – 2012. – T. 167. – No. 5. – pp. 609-618.

Ryodi E. et al. Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy // Thyroid. – 2018. – T. 28. – No. 9. – pp. 1111-1120.

Osman F. et al. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study //Journal of the American College of Cardiology. – 2007. – T. 49. – No. 1. – pp. 71-81.

Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. doi: 10.1089/thy.2016.0229. Erratum in: Thyroid. 2017 Nov;27(11):1462. doi: 10.1089/thy.2016.0229.correx.

Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. //N Engl J Med. 1982 Nov 4;307(19):1165-70. doi: 10.1056/NEJM198211043071901.

Hrnciar J. Cor thyreotoxicum. Part I--new findings about its etiopathogenesis and diagnosis. Overview of problems based on 35 years' experience //Vnitrni Lekarstvi. – 2002. – T. 48. – No. 1. – pp. 38-44.

Roffi M., Cattaneo F., Topol EJ Thyrotoxicosis and the cardiovascular system: subtle but serious effects // Cleveland Clinic journal of medicine. – 2003. – T. 70. – No. 1. – pp. 57-63.

Albakri A. Thyrotoxic heart failure: a review of clinical status and meta-analysis of electrocardiogram diagnosis and medical clinical management methods //Integr Mol Med. – 2018. – T. 5. – No. 6. – P. 1-11.

Vydt T, Verhelst J, De Keulenaer G. Cardiomyopathy and thyrotoxicosis: tachycardiomyopathy or thyrotoxic cardiomyopathy? //Acta Cardiol. 2006 Feb;61(1):115-7. doi: 10.2143/AC.61.1.2005149.